What countries need: Investments needed for 2010 targets
Getting to Zero
Sustainable Financing of National HIV Responses
Scientific Brief, 17 June 2020
Investigación original / Original research
Rev Panam Salud Publica 36(3), 2014
Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework
Informe Conjunto de Organizaciones de Defensa del Derecho a la Salud al Comité de Derechos Económicos y Sociales de las Naciones Unidas, con motivo del Examen del 3er Informe Periódico del Estado Venezolano en el Período de Sesión 55° del Pacto Internacional de Derechos Económicos, Sociales y... Culturales
more
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
Servicios de Salud locales, distritales, regionales y Unidades de salud de la Familia.
Meeting report, Kampala, Uganda,
7–8 November 2023
Journal of The Association of Physicians of India, Vol. 63 November 2015,, pp.77-96
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more